AEs leading to discontinuation of pomalidomide or both treatments, according to system organ class (n = 50)
| AEs leading to discontinuation of pomalidomide or both treatments . | n (%) . |
|---|---|
| Blood and lymphatic system disorders | |
| Anemia | 1 (2) |
| Neutropenia | 1 (2) |
| Febrile neutropenia | 1 (2) |
| Thrombocytopenia | 1 (2) |
| Musculoskeletal and connective tissue disorders | 2 (4) |
| Bone pain | 2 (4) |
| Pulmonary embolism | 1 (2) |
| Infections | 4 (8) |
| Septic shock | 3 (6) |
| AEs leading to discontinuation of pomalidomide or both treatments . | n (%) . |
|---|---|
| Blood and lymphatic system disorders | |
| Anemia | 1 (2) |
| Neutropenia | 1 (2) |
| Febrile neutropenia | 1 (2) |
| Thrombocytopenia | 1 (2) |
| Musculoskeletal and connective tissue disorders | 2 (4) |
| Bone pain | 2 (4) |
| Pulmonary embolism | 1 (2) |
| Infections | 4 (8) |
| Septic shock | 3 (6) |